Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

10.50
+0.24002.34%
Post-market: 10.500.00000.00%19:30 EDT
Volume:752.20K
Turnover:7.90M
Market Cap:652.67M
PE:-8.41
High:10.72
Open:10.15
Low:10.15
Close:10.26
52wk High:11.15
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:0.91
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.55
PE(LYR):-6.65

Loading ...

UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults

THOMSON REUTERS
·
Jun 03

Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults

Reuters
·
May 27

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

GlobeNewswire
·
May 27

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Sagimet Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 19

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

TIPRANKS
·
May 19

Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer

Reuters
·
May 15

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 14

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

TIPRANKS
·
May 14

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 13

Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

BRIEF-Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates

Reuters
·
May 12

Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate

Benzinga Earnings
·
May 12

Sagimet Q1 FY26 net loss narrows to $10.7 million; R&D expense drops to $7 million

Reuters
·
May 12

Press Release: Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
May 12

Sagimet plans U.S. Phase 3 denifanstat acne trial start in H2 2026

Reuters
·
May 11

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

GlobeNewswire
·
May 11

Sagimet Biosciences Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 08